Please use this identifier to cite or link to this item: http://nopr.niscair.res.in/handle/123456789/33808
Title: Role of protein tyrosine kinase inhibitors in cancer therapeutics
Authors: Bhise, S B
Nalawade, Abhijit D
Wadhawa, Hitesh
Keywords: Protein tyrosine kinase;Tyrosine kinase inhibitors;Imatinib mesylate;Chronic myeloid leukemia;Acute myeloid leukemia;Anticancer agent;Gastrointestinal stromal tumor;Epidermal growth factor receptor;Vascular endothelial growth factor
Issue Date: Dec-2004
Publisher: NISCAIR-CSIR, India
Abstract: Protein tyrosine kinases (PTKs) are critical in regulating cell growth and differentiation and are deeply involved in several cancers. PTK-inhibitors are mainly ATP-site directed and are finding use in the treatment of several cancers, and more than 30 such agents are now in phase I-III clinical trials. The present review focuses mainly on the development of PTK inhibitors in clinical trials, with special emphasis on imatinib mesylate, a rationally designed, potent oral anticancer agent and selective inhibitor for Abl tyrosine kinase, including Bcr-Abl, C-kit and platelet-derived growth factor-receptor tyrosine kinases, which has been implicated in several malignancies, including chronic myeloid leukemia and gastrointestinal stromal tumour.
Page(s): 273-280
URI: http://hdl.handle.net/123456789/33808
ISSN: 0975-0959 (Online); 0301-1208 (Print)
Appears in Collections:IJBB Vol.41(6) [December 2004]

Files in This Item:
File Description SizeFormat 
IJBB 41(6) 273-280.pdf1.78 MBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.